Atazanavir Causing CNS Toxicity? Unexplained Neurological Symptoms in Two Patients Recently Started on Atazanavir

Toby M*
Guy’s and St Thomas’ Hospital, NHS Foundation Trust, London, UK

Abstract
To date only one published case report exists of the HIV protease inhibitor atazanavir (ATV) causing central nervous system (CNS) side effects. We report two such cases of patients experiencing disabling CNS side effects shortly after starting ATV-containing regimens whose symptoms only resolved after withdrawing the drug.

Case
A 39-year-old, homosexual man from the Philippines was diagnosed with HIV (no resistance mutations, CD4 count 315 cells/µl, HIV viral load 120,033 copies/ml) and hepatitis B (HBV) infections (HBV e antigen negative, HBV DNA 2349 IU/ml). Three months after diagnosis he was started on a one-pill combination regimen of tenofovir, emtricitabine and efavirenz (TDF/FTC/EFV). After 10 days he developed a widespread erythematous rash without mucosal involvement and TDF/FTC/EFV was stopped immediately. Routine biochemistry and hematology blood tests done at this time were all within normal limits and he was started on a new regimen of TDF/FTC and ritonavir-boosted atazanavir (ATV/r; 300 mg/100 mg) once daily.

He returned to the clinic 2 weeks later complaining of weakness, mild headache, agitation and difficulty sleeping in the first week of taking his new regimen. This had progressed and after the second week, 4 hours after taking his antiretrovirals in the morning he became disoriented in time and place, described severe vertigo and became tremulous. These episodes occurred for 5 consecutive days and lasted approximately 3 hours each time.

He tried taking his antiretrovirals at night; his partner reported that 3 hours after taking the medication he woke up from sleep completely disoriented and complained of nausea and extreme vertigo rendering him unable to walk. The patient stopped his antiretrovirals of his own volition after this night-time episode. He was seen in clinic 48 hours later by which time he was completely asymptomatic; he was afebrile with a normal physical examination. Hematological and biochemistry blood tests were unremarkable apart from an elevated alanine aminotransferase (ALT) of 127 IU/L (4-59 IU/L).

The patient’s symptoms were attributed to ATV and not FTC having not experienced these symptoms taking FTC previously. His regimen was changed to FTC/TDF and ritonavir-boosted darunavir (DRV/r; 800 mg/100 mg) and he was seen 2 weeks later in clinic. He reported no further symptoms and his ALT had returned to normal.

A second patient was an Ecuadorian woman diagnosed HIV positive with a CD4 count of 10 cells/µl at diagnosis. She was thus started on TDF, lamivudine (3TC) and lopinavir/ritonavir (LPV/r; 400 mg/100 mg). She had remained stable on this regimen for 2 years with virological suppression to less than 50 copies/ml. She requested simplification of the regimen due to high pill burden and twice daily dosing and her LPV/r was thus switched to ATV/r 300 mg/100 mg along with her existing TDF and 3TC.

The patient returned to clinic after 10 days complaining of mild dizziness in the first week, which progressed to severe positional vertigo, tremulousness and nausea in the second week. The examination was unremarkable but turning her head provoked extreme vertigo. She was apyrexial and all other vital signs were within normal limits. Routine biochemistry and hematology blood tests done at this time were within normal parameters as were her inflammatory markers. As the only recent change had been the ATV switch it was felt her symptoms were attributable to this. She was switched back to her previous regimen of TDF, 3TC and LPV/r and seen 1 week later, by which time her symptoms had subsided completely.

Discussion
To our knowledge there is only one published case report of similar side effects in a patient taking ATV. In this case the patient had a 3-year history of ATV, 3TC and TDF use and was admitted to hospital for objective vertigo, nausea and sweating triggered by postural changes. He was diagnosed as having lithiasis of his posterior semicircular canal, possibly related to his ATV use [1].

It is well known that ATV/r is associated with renal lithiasis and there have been reports of ATV-associated choledocholithiasis [2-4]. We can postulate that our patients may have had semicircular canal lithiasis causing similar symptoms, though the short duration between onset and starting the drug and the complete resolution of symptoms after stopping the drug make this mechanism less likely.

It is known that cerebro-spinal fluid (CSF) concentrations of ATV are usually 100-fold lower than plasma concentrations. If CSF concentrations are a reasonable surrogate marker for antiretroviral drug levels in the brain we should expect lower levels of CNS toxicity [5,6]. This has however been refuted by a recent US study examining antiretroviral neurotoxicity using sensitive indices of neural damage which found that highest neurotoxicities were associated with abacavir, efavirenz, etravirine, nevirapine and atazanavir [7].

One limitation of this report is that a clinical diagnosis was made...
prior to employing investigative methods for assessing the cause of vertigo such as using the Dix Hallpike manoeuvre to aid in the diagnosis of benign paroxysmal positional vertigo. A MRI may also have been useful in the first patient to exclude diffuse CNS involvement. A further limitation is that ATV levels may have been helpful in both cases to ascertain if toxic serum concentrations of the drug could provide an explanation for the symptoms.

**Conclusion**

Our cases demonstrate possible treatment-limiting CNS side effects in patients recently started on ATV. Clinicians should consider withdrawing ATV in patients taking the drug if such symptoms occur without another clear aetiology.

**References**

1. Pastori D, Esposito A, Cagliuso M, Conti V, Mezzaroma I (2009) Lithiasis of semicircular canals and parotid glands: unusual stones deposition in atazanavir-treated individuals. AIDS 23: 2233-2234.

2. Rockwood N, Mandalia S, Bower M, Gazzard B, Nelson M (2011) Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS 25: 1671-1673.

3. Couzigou C, Daudon M, Meynard JL, Borsa-Lebas F, Higueret D, et al. (2007) Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis 45: e105-108.

4. Jacques AC, Giguerre P, Zhang G, Touchie C, la Porte CJ (2010) Atazanavir-associated choledocholithiasis leading to acute hepatitis in an HIV-infected adult. Ann Pharmacoter 44: 202-206.

5. Best BM, Letendre SL, Brigid E, Clifford DB, Collier AC, et al. (2009) Low atazanavir concentrations in cerebrospinal fluid. AIDS 23: 83-87.

6. Randall D, Agarwala S, Mummaneni V, Gerald M, Giordano M, et al. (2002) Tissue compartment concentrations of atazanavir in cerebrospinal fluid, seminal fluid and plasma in HIV R subjects. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy.

7. Robertson K, Liner J, Meeker RB (2012) Antiretroviral neurotoxicity. J Neurovirol 18: 388-399.